Secreted IgM deficiency leads to increased BCR signaling that results in abnormal splenic B cell development. by Tsiantoulas, Dimitrios et al.
1Scientific RepoRts | 7: 3540  | DOI:10.1038/s41598-017-03688-8
www.nature.com/scientificreports
Secreted IgM deficiency leads 
to increased BCR signaling that 
results in abnormal splenic B cell 
development
Dimitrios Tsiantoulas1,2, Mate Kiss1,2, Barbara Bartolini-Gritti1,2, Andreas Bergthaler1, Ziad 
Mallat  3, Hassan Jumaa4 & Christoph J. Binder1,2
Mice lacking secreted IgM (sIgM−/−) antibodies display abnormal splenic B cell development, which 
results in increased marginal zone and decreased follicular B cell numbers. However, the mechanism 
by which sIgM exhibit this effect is unknown. Here, we demonstrate that B cells in sIgM−/− mice display 
increased B cell receptor (BCR) signaling as judged by increased levels of phosphorylated Bruton’s 
tyrosine kinase (pBtk), phosphorylated Spleen tyrosine kinase (pSyk), and nuclear receptor Nur77. 
Low dosage treatment with the pBtk inhibitor Ibrutinib reversed the altered B cell development in the 
spleen of sIgM−/− mice, suggesting that sIgM regulate splenic B cell differentiation by decreasing BCR 
signaling. Mechanistically, we show that B cells, which express BCRs specific to hen egg lysozyme (HEL) 
display diminished responsiveness to HEL stimulation in presence of soluble anti-HEL IgM antibodies. 
Our data identify sIgM as negative regulators of BCR signaling and suggest that they can act as decoy 
receptors for self-antigens that are recognized by membrane bound BCRs.
Secreted IgM (sIgM) antibodies are produced very early in life. A significant part of total IgM are natural IgM, 
which are produced by innate B-1 B cells in absence of cognate T cell help. SIgM has a pentameric structure, 
which allows for strong interactions with its antigens1, 2. Besides the well documented protective role of sIgM 
against invading microbial pathogens1, 2, these antibodies exhibit also a crucial regulatory role in B cell homeosta-
sis under unchallenged conditions. For instance, marginal zone (MZ) B cells are increased in mice lacking sIgM 
antibodies (sIgM−/−), whereas follicular (FO) B cells are decreased3, 4. However, the mechanisms by which sIgM 
control splenic B cell differentiation are unknown.
FO and MZ B cells (both termed B-2 cells) arise in the spleen. They display major differences with respect 
to their surface receptors, activation properties, circulating capacity and anatomical localization in the spleen. 
For example, in contrast to MZ, FO B cells, express on their surface the low affinity receptor for IgE (CD23), 
have circulating capacity and thus are the major source of recirculating mature B cells5. MZ B cells resign in the 
marginal zone, express higher levels of the complement receptor 2 (CD21) than FO B cells and respond rapidly 
to blood-borne antigens6.
Both MZ and FO B cells emerge upon maturation of transitional B cells, which have successfully escaped from 
the bone marrow selection5. The major driver of the developmental fate of transitional B cells towards MZ and 
FO B cells is most likely the self-antigen induced B cell receptor (BCR) signaling strength. BCR is present on the 
cell surface in two isotypes with identical specificity, the IgM and IgD7. However, while IgM can be secreted, IgD 
is only found in membrane-bound form. It still remains unclear what the effect of BCR signaling strength is in 
mature B cell development. Some studies suggested that strong BCR signaling promotes FO, whereas weak BCR 
signaling favors MZ B cell development5. For example, mice lacking Bruton’s tyrosine kinase, which is a crucial 
mediator of BCR signaling, show reduced total numbers of MZ and FO B cells. However, the MZ population 
seemed to be less affected than the FO population, which led to the conclusion that strong BCR signaling might 
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promote FO and restrict MZ B cell development8. On the other hand, it has been shown using a monoclonal BCR 
tg mouse specific for the self-antigen Thy-1, that in presence of the self-antigen, and thus presumably stronger 
BCR signaling, MZ B cell is favored over FO B cell development9. Notably, we and others have shown that sIgM 
bind to cellular debris and apoptotic cells10, 11, which are prototypic sources of self-antigens. Thus, sIgM could 
influence BCR signaling strength by modulating the interaction of BCRs with circulating self-antigens.
We here investigated the role of sIgM in BCR signaling and how this impacts splenic B-2 cell maturation. We 
demonstrate that in absence of sIgM, splenic B-2 cells display increased BCR signaling, which is responsible for 
the abnormal B cell development. Moreover, we show that antigen specific sIgM limit the exposure of BCRs to 
self-antigens resulting in reduced BCR activation. Our data indicate that sIgM facilitate proper B cell develop-
ment by acting as negative regulators of BCR signaling. Mechanistically, sIgM have the capacity to limit the bind-
ing of self-antigens to membrane bound BCRs by acting as decoy receptors and thereby modulate BCR signaling.
Results
sIgM−/− mice display abnormal splenic B-2 cell development. In agreement with previous reports3, 
4 we found increased numbers of marginal zone (MZ) and CD21+ CD23− B cells, while CD23 expressing transi-
tional stage 2 and follicular (FO/T2) B cells were strongly decreased in sIgM−/− mice (Fig. 1a and Fig. S1). Newly 
formed (NF) and transitional stage B cells were not different between sIgM−/− and sIgM+/+ mice (Fig. 1a and 
Fig. S1). Moreover, short-term infusion of wild-type polyclonal IgM into sIgM−/− mice could partially reverse the 
increased MZ and decreased FO B cells (Fig. 1b), which suggests that sIgM influence B cell development during 
differentiation in the spleen. In line with this, CD21+ CD23− B cells remained increased in sIgM−/− mice even 
after excluding transitional B220+CD93+ B cells from the analysis (Fig. 1c). This suggests that there is an accumu-
lation of mature B cells at this stage, suggesting an impaired ability to differentiate towards FO B cells. Consistent 
with this, we found that CD21+ CD23− B cells in sIgM−/− mice display increased Blimp-1 levels (Fig. 1d), which is 
consistent with our previous work showing that increased Blimp-1 levels result in suppression of CD23 expression 
in B cells12. Interestingly, we also found that splenic B cells of sIgM−/− mice display a decreased kappa to lambda 
light chain ratio compared to sIgM+/+ mice (Fig. 1e). However, while similar data were obtained in mature circu-
lating B cells in the bone marrow (Fig. 1f), immature bone marrow B cells exhibit an equivalent kappa to lambda 
light chain ratio in sIgM−/− and sIgM+/+ mice (Fig. 1f). These data suggest that the abnormal splenic B cell mat-
uration is not due to an altered BCR repertoire occurring upon BCR editing in the bone marrow level. Because 
we found no differences in total numbers of splenic B220+IgM+ (sIgM+/+, 58 ± 9 × 106; sIgM−/−, 54 ± 6 × 106), 
CD19+ (sIgM+/+, 59 ± 9 × 106; sIgM−/−, 62 ± 7 × 106), and CD19+7-AAD+ dying (sIgM+/+, 3 ± 0.6 × 106; sIgM−/−, 
3 ± 0.5 × 106) B cells, we hypothesized that the abnormal B cell development may be due to altered BCR signaling 
strength, which is the key driver of splenic B cell development towards MZ or FO B cells5, 13.
Secreted IgM deficiency results in enhanced BCR signaling. To investigate possible differences in 
BCR signaling, we quantified the levels of phosphorylated spleen tyrosine kinase (pSyk) and Bruton’s tyros-
ine kinase (pBtk) in splenic B cell subsets of sIgM+/+ and sIgM−/− mice by flow cytometry. These kinases have 
been shown to be critically involved in antigen mediated BCR signaling and B cell maturation towards FO and 
MZ B cells8, 14, 15. Both MZ and FO/T2 exhibited higher levels of both pSyk and pBtk in sIgM−/− mice. Similar 
results were obtained for CD21+ CD23− splenic B cells (Fig. 2a,b). Notably, NF and T1 B cells, which rely mainly 
on “tonic” (antigen independent) BCR signaling for their survival5, displayed similar levels of pSyk and pBtk 
in sIgM+/+ and sIgM−/− mice (Fig. 2a,b). To confirm our results, we quantified the expression of the nuclear 
receptor Nur77 as a marker of BCR signaling intensity16 in splenic B cell subsets of Nur77-GFP/sIgM−/− and 
Nur77-GFP/sIgM+/+ reporter mice. Consistent with the increased levels of pBtk and pSyk, we found higher Nur77 
expression in MZ, FO/T2 and CD21+ CD23− B cells of sIgM−/− mice, whereas NF and T1 B cells showed no dif-
ference (Fig. 2c). These data show that mature B-2 cells display increased BCR signaling in sIgM−/− mice.
To investigate further whether enhanced BCR signaling is the cause of abnormal B cell maturation in absence 
of sIgM, we treated sIgM−/− mice with a low dose of the Btk inhibitor Ibrutinib for two weeks. Vehicle treated 
sIgM−/− and sIgM+/+ mice served as controls. Ibrutinib treatment17 did not alter body weight (sIgM−/− + vehi-
cle, 25.7 ± 1.6 g; sIgM−/− + Ibrutinib 26.1 ± 0.6 g) or total B-2 cell numbers (sIgM−/− + vehicle, 56 ± 2 × 106; 
sIgM−/− + Ibrutinib 50 ± 2 × 106), but rescued the abnormal B-2 cell differentiation kinetics in sIgM−/− mice by 
decreasing the frequencies of CD21+ CD23− B cells and MZ B cells, and concomitantly increasing the frequency of 
FO B cells (Fig. 2d). Notably, Ibrutinib did not affect NF (sIgM−/− + vehicle, 2.3 ± 0.3%; sIgM−/− + Ibrutinib, 
2.3 ± 0.4% out of B220+ CD43− B cells) and T1 (sIgM−/− + vehicle, 6.6 ± 0.8%; sIgM−/− + Ibrutinib, 7.3 ± 0.9% 
out of B220+ CD43− B cells) B cells. These data indicate that sIgM prevent excessive BCR signaling in mature B-2 
cells and thereby facilitate their proper differentiation towards MZ and FO B cells.
Importantly, our data also suggest that strong BCR signaling promotes MZ over FO B cell development. 
Indeed, our analyses of BCR signaling demonstrate that MZ B cells (light purple bar) display substantially higher 
pSyk and pBtk levels than FO/T2 B cells (light blue bar) in sIgM+/+ mice (Fig. 2a,b). Similarly, Nur77 expression 
was higher in MZ B cells (light purple bar) compared to FO/T2 B cells (light blue bar) in Nur77-GFP/sIgM+/+ 
reporter mice (Fig. 2c). To investigate this further, we treated sIgM+/+ mice with Ibrutinib for 2 and 3 weeks 
and assessed the distribution of MZ and FO B cell in the spleen. Ibrutinib treatment in sIgM+/+ mice, did not 
affect their body weight (2-week treatment; sIgM+/+ + vehicle, 21.2 ± 0.7 g; sIgM+/+ + Ibrutinib 19.5 ± 0.7 g and 
3-week treatment sIgM+/+ + vehicle, 20.8 ± 0.37 g; sIgM+/+ + Ibrutinib 21 ± 0.5 g) and total B-2 cell numbers 
(2-week treatment; sIgM+/+ + vehicle, 68 ± 10 × 106; sIgM+/+ + Ibrutinib 68 ± 8 × 106 and 3-week treatment; 
sIgM+/+ + vehicle, 108 ± 3 × 106; sIgM+/+ + Ibrutinib 98 ± 12 × 106). However, compared to vehicle treated con-
trols Ibrutinib treatment of sIgM+/+ mice lead to an altered B-2 cell differentiation profile, characterized by a 
robust reduction of MZ B cells already after 2-weeks treatment and a proportional increase of FO B cells that 
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became evident after 3-weeks treatment (Fig. 3a,b). These data suggest that lowering BCR signaling limits MZ and 
promotes FO B cell development also in sIgM+/+ mice.
Antigen-specific secreted IgM dampen self-antigen induced BCR signaling. Because sIgM rec-
ognize different types of self-antigens such as cellular debris and apoptotic cells10, 11, we investigated if sIgM 
antibodies modulate BCR signaling in a self-antigen mediated manner. For this purpose, we employed the 
model of MD4 transgenic mice that express BCRs directed against hen egg lysozyme (HEL). MD4 B cells pro-
duce HEL-specific IgM antibodies (Fig. 4a), while they lack the ability to class switch to other immunoglobulin 
isotypes18. Stimulation of purified MD4 B-2 cells with HEL in the presence of plasma from either WT (grey 
bars) or RAG1−/− (purple bars) mice resulted in a robust BCR activation as measured by increased levels of 
pBtk (Fig. 4b). In contrast, HEL stimulation in presence of plasma from MD4 mice (blue bars) failed to trigger 
BCR signaling (Fig. 4b). These data suggest that HEL-specific IgM antibodies present in MD4 plasma prevent 
self-antigen induced BCR activation. To investigate this further, we depleted HEL-specific IgM antibodies from 
Figure 1. sIgM deficiency results in altered splenic B cell development. (a) Representative flow cytometry plots 
and bar graphs show absolute numbers of FO/T2 (blue), MZ (purple), CD21+ CD23− B cells (red), T1 (green) 
and NF (grey) cells (defined in Fig. S2) of sIgM+/+ (light colored bars) and sIgM−/− (dark colored bars) mice. 
(b) Representative flow cytometry plots and dot plots show the frequencies of MZ (purple) and FO/T2 (blue) 
B cells of sIgM+/+ (●) and sIgM−/− (▼) mice treated with vehicle and sIgM−/− (▲) treated with polyclonal 
IgM (n = 4–5 mice per group). (c) Absolute numbers of splenic B220highCD93−CD21+ CD23− B cells and (d) 
Blimp-1 mean fluorescence intensity (MFI) in CD21+ CD23− B cells of sIgM+/+ (light red bar) and sIgM−/− 
(dark red bar) mice analyzed by flow cytometry. (e,f) Representative flow cytometry plots show the percentages 
of either kappa or lambda light chain positive and bars represent the mean kappa/lambda light chain ratio of 
(e) B220+CD43− splenic cells and (f) mature (B220high CD43−) and immature (B220low CD43−) bone marrow 
cells within cells that express BCR. (a,c–f) Data shown are from one representative experiment of at least two to 
three independent experiments with 5–6 mice per group. All results show mean ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001 (Mann-Whitney or unpaired t test or One-Way Anova test followed by Tukey’s 
test).
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MD4 plasma using microspheres coated with HEL protein. Treatment with HEL-coated microspheres resulted in 
a complete depletion of HEL-specific IgM, but only a moderate reduction of total IgM, whereas sham-treated or 
BSA-coated microspheres had no effect (Fig. 4c,d). Notably, MD4 plasma depleted of HEL-specific IgM failed to 
inhibit HEL-dependent BCR stimulation in purified MD4 B-2 cells, while this was not the case for MD4 plasma 
treated with either sham-treated or BSA-coated microspheres (Fig. 4e). Thus, sIgM have the capacity to limit 
self-antigen induced BCR signaling in an antigen specific manner.
Discussion
The mechanism by which sIgM exhibits its regulatory role in mature B-2 cell development is not known. We 
demonstrate here that sIgM facilitate proper BCR signaling and thereby physiological differentiation of splenic 
mature B-2 cells. Mechanistically, we demonstrate that antigen-specific sIgM have the capacity to reduce BCR 
signaling by limiting the exposure of self-antigens to BCR.
BCR signaling strength is a major determinant of the developmental fate of mature splenic B cells5. Data on 
how BCR signaling strength influences MZ and FO B cell development are contradictory and numerous studies 
suggest a direct association between BCR signaling strength and FO B cell differentiation. In contrast, our find-
ings indicate that strong BCR signaling favors MZ and restricts FO B cell development. We show that MZ B cells 
display increased pBtk, pSyk and Nur77 expression than FO B cells in vivo. Furthermore, low-dose Ibrutinib 
treatment, which blocks Btk and lowers BCR signaling, promoted FO and restricted MZ B cell formation in 
sIgM+/+ mice. In addition, we demonstrate that increased BCR signaling in sIgM−/− mice results in an expansion 
Figure 2. sIgM deficiency results in increased B cell receptor signaling in vivo. Representative flow cytometry 
plots and bar graphs show (a–c) the mean fluorescence intensity (MFI) for pSyk, pBtk levels and Nurr77-GFP 
expression in FO/T2 (blue), MZ (purple), CD21+ CD23− (red), T1 (green) and NF (grey) B cells (as defined in 
Fig. S2) of sIgM+/+ or Nur77-GFP/sIgM+/+ (light colored bar) and sIgM−/− or Nur77-GFP/sIgM−/− (dark colored 
bar) mice. Data shown are from one representative experiment (a,b) or pooled (c) from two/three independent 
experiments. (d) Representative flow cytometry plots and dot plots show the frequencies of CD21+ CD23− 
(red), FO (blue) and MZ (purple) B cells within B-2 cells of sIgM+/+ (●) and sIgM−/− (▼) mice treated with 
vehicle, and sIgM−/− (▲) mice treated with the Btk inhibitor Ibrutinib. All results show mean ± SEM, n = 4–6 
mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (unpaired or paired t test or One-Way 
Anova test followed by Tukey’s test).
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Figure 3. Ibrutinib treatment limits MZ and favors FO B cell development in sIgM+/+ mice in vivo. 
Representative flow cytometry plots and dot plots represent the frequencies of MZ (purple) and FO (blue) B 
cells within B-2 cells of sIgM+/+ mice treated with vehicle (●) or the Btk inhibitor Ibrutinib (▲) for (a) 2 weeks 
or (b) 3 weeks. All results show mean ± SEM, n = 4–5 mice per group. *P < 0.05, **P < 0.01 (unpaired t test).
Figure 4. Antigen-specific secreted IgM limit self-antigen induced B cell receptor signaling. (a) Quantification 
of hen egg-white lyoszyme (HEL) specific IgM in the plasma of MD4, RAG1−/− and wild-type (WT) mice by 
ELISA. (b) Representative flow cytometry plots and bar graphs represent the mean fluorescence intensity (MFI) 
for pBtk in purified B-2 (B220+ CD43−) cells from MD4+/− mice stimulated with HEL for 3 minutes in presence 
of either WT (grey), RAG1−/− (purple) or MD4 plasma (blue). ELISA quantification of (c) HEL-specific and 
(d) total IgM in MD4 plasma treated with either unconjugated or BSA- or HEL-conjugated microspheres. (e) 
Representative flow cytometry plots and bar graphs show the MFI for pBtk in purified B-2 cells from MD4+/− 
mice stimulated with HEL for 3 minutes in the presence of plasma from MD4 mice that has been treated with 
either unconjugated or BSA- or HEL-conjugated microspheres. All results show mean ± SEM, ****P < 0.0001 
(unpaired t test or One-Way Anova followed by Tukey’s test). n.d.: not detechtable.
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of MZ and a reduction of FO B cells, which was reversed upon Ibrutinib treatment. Thus, our data document that 
MZ and FO B cell differentiation is promoted by a constitutively strong and weak BCR signaling, respectively.
Although, weak BCR signaling has been proposed to be the cause of impaired FO B cell generation in mice 
lacking Btk or PLC-γ213, 19, it is important to note that in these mice MZ B cell numbers seem to be less13 or even 
not affected19. This suggests that reduced FO B cell development in this setting might be a result of impaired 
survival rather than disturbed B cell differentiation per se, likely due to complete absence of Btk. Along this line, 
B cell specific deletion of the Lyn kinase, which would increase BCR signaling and according to the current view 
would promote FO B cell formation, results in strong reduction of both FO and MZ B cells20, which further sup-
ports the hypothesis that complete lack of such kinases impacts predominately cell survival and thus does not 
allow safe conclusions on their role with respect to B cell differentiation. On the other hand, we provide evidence 
that reducing the phosphorylation of Btk in vivo with a low dosage of Ibrutinib shifts the differentiation towards 
FO at the expense of MZ B cells.
CD21+ CD23− B-2 cells, which were increased in sIgM−/− mice may function as a reservoir for the develop-
ment of FO and MZ B cells depending on the BCR signaling strength. In line with this, the increased numbers of 
CD21+ CD23− B-2 cells in sIgM−/− mice may provide an explanation as to why Ibrutinib treatment altered the 
frequency of FO B cells in these mice already after 2 weeks compared to sIgM+/+ mice. Interestingly, we found that 
in sIgM+/+ mice these cells display basal BCR signaling similar to FO B cells, suggesting a higher propensity to 
differentiate towards FO B cells. In sIgM−/− mice, CD21+ CD23− B-2 cell display higher BCR signaling compared 
to FO B cells, which may not be permissive for differentiation towards FO B cells resulting in their accumulation 
at the CD21+ CD23− stage or their preferential differentiation towards MZ B cells. This hypothesis is supported 
by our findings that CD21+ CD23− B cells of sIgM−/− mice display increased levels Blimp-1, which has been 
shown to be expressed to a higher extent in MZ compared to FO B cells21 and to suppress the expression of the 
FO B cell marker CD2312.
We demonstrate that BCR signaling in vivo is significantly increased in the absence of sIgM suggesting that 
sIgM are negative regulators of BCR signaling. Although a previous study proposed decreased basal BCR sign-
aling in isolated CD43− splenic B cells of sIgM−/− mice based on reduced pErk levels22, it has to be kept in mind 
that phosphorylation of Erk in B cells can be induced via multiple pathways independent of BCR signaling23. 
Furthermore, we did not find any differences with respect to T1 B cells between of sIgM−/− and sIgM+/+ mice, 
which is in contrast to a previous study that reported reduced T1 B cell numbers in sIgM−/− mice4. This may be 
a consequence of different flow cytometry gating strategies by Ngyuen et al. who included a large population of 
CD23+ cells in the analysis of T1 B cells4. Notably, T1 B cells do not express CD23 and thus inclusion of this pop-
ulation would result in a reduction in T1 B cells concomitant with a reduction in CD23+ B cells as it is the case in 
sIgM−/− mice. Interestingly, splenic B cells of sIgM−/− mice display decreased and increased levels of IgD and IgM 
BCRs respectively24, 25. However, enhanced or diminished signaling via the IgM or IgD-BCR respectively, cannot 
explain the differences in B cell development seen in sIgM−/− mice, as IgD deficient mice, which still express IgM 
BCRs and sIgM display normal splenic B cell development26. Furthermore, it has been reported that B cells iso-
lated from sIgM−/− mice display similar responsiveness to stimulation with anti-IgM Fab fragments compared to 
sIgM+/+ B cells[22], which further supports that altered surface IgM/IgD expression does not seem to be respon-
sible for the altered BCR signaling.
An alternative possibility by which sIgM influence the B-2 cell development is via the IgM receptor (FcµR). 
However, several independently generated IgM receptor deficient mouse models have yielded inconsistent results 
with respect to B-2 cell development that do not resemble the phenotype of sIgM−/− mice27. For example, it has 
been shown in two independent studies that mice deficient in FcµR develop reduced MZ27, whereas in a recent 
study B cell specific deletion of FcµR lead to increased FO B cells28. These are in contrast with the increased MZ 
and decreased FO B cells seen in sIgM−/− mice. Furthermore, we show mechanistically that HEL-specific sIgM 
are able to prevent HEL-induced BCR activation of MD4 B cells, whereas non HEL-specific IgM, which can still 
bind to the FcµR, failed to do so. In agreement with this, FcµR receptor, which is also expressed in the trans-Golgi 
network, affects tonic B cell receptor signaling by regulating the amount of surface bound IgM28. Taken together, 
we conclude that the sIgM-FcµR signaling axis is not responsible for the disturbed splenic B cell development and 
altered BCR signaling in sIgM−/− mice. In fact, our data suggest that naive B-2 cells secrete IgM that limit their 
exposure to the antigens they recognize in an antigen-specific manner. Although, identities of the self-antigens 
that influence B cell development still remain elusive, our study is in agreement with recent reports suggesting 
that the majority of mature naïve B cells express autoreactive BCRs16. With respect to this, it would be particularly 
interesting to investigate the effect on BCR signaling and B cell developmental fate in sIgM−/− mice that were 
reconstituted with a poly-IgM preparation that is depleted of IgM with specificity for certain self-antigens. Such 
assay would provide interesting insights into the regulatory effect of antigen specific soluble IgM in preventing 
autoreactive B cell activation.
A large amount of total plasma IgM is B-1 cell derived, which have been suggested to display a different and 
limited repertoire compared to B-2 cells2. On the other hand, it should be noted that B-2 cell derived IgM may 
also contribute significantly to the diversity of the polyclonal IgM pool. Nevertheless, the limited repertoire of 
B-1 derived IgM may contain specificities that are capable of limiting self-antigen mediated BCR signaling in B-2 
cells. It is also conceivable that sIgM could present self-antigens to B cells by recognizing an epitope that is differ-
ent from the one the BCR recognizes and thereby increase BCR signaling. However, this would not be in line with 
our findings showing increased BCR signaling in absence of sIgM. In addition, it has been shown that absence of 
secreted IgM leads to increased autoantibody production4, 29, which would be consistent with B cell overactivation 
in response to an increased free self-antigen pool. Further investigations are required to demonstrate the antigen 
sequestering properties of secreted IgM in vivo.
In conclusion, our data indicate that sIgM are important regulators of BCR signaling strength and suggest 
that they exhibit these properties in part by functioning as decoy receptors of membrane bound BCRs in an 
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 3540  | DOI:10.1038/s41598-017-03688-8
antigen-specific manner. These findings may have broader pathophysiological implication considering that we 
recently demonstrated that impaired B cell functions in sIgM−/− mice lead to robustly increased plasma IgE, 
which accelerate atherosclerosis in these mice30.
Materials and Methods
Mice and treatments. sIgM−/− (on 129 background) and RAG1−/− (on C57BL/6 background) mice were 
originally bought from The Jackson Laboratories (USA). SIgM−/− mice were backcrossed onto C57BL/6 back-
ground for at least 10 generations. MD4 Ikzf1(fl/+) mice were a kind gift from Dr. Busslinger (IMP, Vienna, Austria). 
Apoe−/−/Nur77-GFP reporter mice31 (on C57BL/6 background) were kindly provided by Dr. Norbert Gerdes 
(LMU, Munich, Germany). Nur77-GFP/sIgM−/− mice were generated by intercrossing Apoe−/−/Nur77-GFP 
and sIgM−/− mice. Experiments were performed only with Nur77-GFP/sIgM−/− and Nur77-GFP/sIgM+/+ mice 
that were either Apoe+/+ or Apoe+/−. All mice were bred in our in-house breeding facility. All experiments were 
performed with age and sex matched mice. Experiments were done with mice between 11–20 weeks of age. 
All experimental studies were approved by the Animal Ethics Committee of the Medical University of Vienna 
(Austria) BMWF-66.009/0157-II/3b/2013 and BMWFW-66.009/0030-WF/V/3b/2016. All experiments were 
performed according to the guidelines for Good Scientific Practice of the Medical University of Vienna (Austria).
Flow cytometry. Bone marrow cells were isolated from the tibia and the femur bones on cell strainers with 
100 µm diameter (BD Biosciences), and erythrocytes were lysed upon incubation with erythrocyte lysis buffer 
(MORPHISTO). Isolated spleens were mechanically dissociated in single cell suspensions using cell strainers with 
100 µm diameter (BD Biosciences), and erythrocytes were lysed as above. Cells were added in a 96 well V-bottom 
plate (Thermo Scientific) and incubated for 20 min at 4 °C, with 2.5 µg/ml of a blocking anti-CD16/32 antibody 
(clone 93; eBiosciences) diluted in DPBS (Sigma) containing 10% FBS (FACS buffer). After two washing steps 
with FACS buffer (393 g for 3 minutes at 4 °C), cells were stained with different combinations of the following 
antibodies: anti-B220 PercP-Cy5.5 (clone RA3-6B2; eBiosciences), anti-CD23 FITC, anti-CD23 eFluor450 (clone 
B3B4; eBiosciences), anti-CD43 PE (clone S7; BD Biosciences), anti-IgM APC, anti-IgM FITC (clone II/41; eBio-
sciences), anti-CD21 biotinylated (clone 7E9; Biolegend), anti-CD93 PE (clone AA4.1; eBiosciences), anti-CD19 
PE (clone 1D3; BD Biosciences), anti-kappa FITC (clone 187.1; BD Biosciences), anti-lambda biotinylated (clone 
RML-42; Biolegend), streptavidin APC or streptavidin eFluor 450 (eBiosciences).
To determine the amount of Blimp-1 and of phosphorylated kinases pBtk and pSyk, cells were fixed and 
permeabilized with fixation and permeabilization solution (Miltenyi or eBiosciences) for 30 minutes at 4 °C and 
then stained intracellularly in permeabilization buffer (Milteny or eBiosciences) with the following antibodies: 
anti-Blimp-1 Alexa Fluor 647 (clone 5E7; BD Biosciences), pBTK/ITK (Y551/Y511) APC (clone M4G3LN; eBi-
osciences) and pSYK (Y348) APC (clone moch1ct, eBiosciences). Finally, to identify dead cells staining with 
7-AAD viability solution (eBiosciences) was performed where indicated. Data were acquired on a FACS Calibur 
(BD Biosciences) or LSR Fortessa (BD Biosciences) and were analyzed using Flow Jo software 7.6 (Treestar).
Total and hen egg-white lysozyme specific IgM ELISA. Total and HEL specific IgM in plasma were 
measured by ELISA. Briefly, 96-well white round-bottomed MicroFluor microtiter plates (Thermo Lab systems) 
plates were coated with either 5 µg/ml of an anti-mouse IgM (Sigma; M8644) or with 1 µg/ml of HEL (Sigma) in 
DPBS overnight and then washed 3 times with PBS/EDTA and blocked with Tris-buffered saline containing 1% 
BSA (TBS/BSA) for 1 h at room temperature. After washing the plates as before, diluted murine plasma was added 
in TBS/BSA to the wells and incubated for 1 hour at room temperature. Plates were washed and bound total or 
HEL-specific IgM were detected with an anti-mouse IgM antibody conjugated to alkaline phosphatase (Sigma; 
A9688). Wells were washed again as before and rinsed once with distilled water, and 25 µl of a 30% LumiPhos 
Plus solution in dH20 (Lumigen Inc) was added. After 75 min the light emission was measured with a Synergy 2 
luminometer (BIO-TEK) and expressed as RLU per 100ms.
Polyclonal IgM treatment. Female sIgM−/− mice (n = 5) were injected intraperitoneally six times, every 
two days for two weeks with 200 µg/mouse of polyclonal IgM (Rockland) diluted in 100 µl DPBS (Sigma) and 
compared to sIgM−/− (n = 4) and sIgM+/+ (n = 4) mice that were injected with DPBS only. At the end of the treat-
ment mice were sacrificed and flow cytometric analysis of splenic B cell subsets was performed.
Ibrutinib treatment. sIgM−/− mice were treated with the Btk inhibitor Ibrutinib (PCI-32765; 25 mg/kg/
day/mouse; n = 4) diluted in drinking water containing 5% D-Mannitol (Sigma) and 0.5% gelatin (Sigma) or 
vehicle only (n = 4) for 2 weeks by oral gavage. Control sIgM+/+ mice (n = 4) were treated with the vehicle only. 
In two independent experiments sIgM+/+ mice (n = 5) were treated for 2 or 3 weeks with the vehicle or Ibrutinib 
(n = 4–5) as above. All mice were fasted for 2 hours before every administration. At the end of the treatment mice 
were sacrificed and flow cytometric analysis of splenic B cell subsets was performed.
MD4 B cell stimulation with hen egg-white lysozyme (HEL). Untouched B-2 cells from MD4+/− 
mice were purified with the B cell isolation kit (Miltenyi), and purified MD4 B cells (3 × 105/well) were stimulated 
in triplicates with different concentrations of HEL (Sigma), in the presence of either wild-type, RAG1−/− or MD4 
plasma diluted 1:10 in RPMI supplemented with 10% FBS and 1% penicillin/streptomycin for 3 minutes at 37 °C. 
In some experiments, MD4 plasma was treated with either unconjugated, BSA or HEL-conjugated polystyrene 
microspheres (Polysciences) to absorb HEL-specific antibodies and used at a dilution of 1:30. Protein conjugation 
on the surface of microspheres was achieved using the glutaraldehyde method according to the manufacturer’s 
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instructions. At the end of the stimulation, cells were immediately fixed, permeabilized and stained for B220 and 
pBtk as described above.
Statistical analyses. Statistical analyses were performed using Graph Pad Prism 5 for Windows (Graph 
Pad Software). Experimental groups were compared using two tailed Student’s unpaired or paired t test or 
Mann-Whitney U test as appropriate. To analyze multiple group data One-Way ANOVA test followed by Tukey’s 
test was performed. Data are presented as mean ± SEM. A P value of <0.05 was considered significant.
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